| 臺大學術典藏 |
2020-04-10T12:51:14Z |
Factors impacting prognosis prediction in BCLC stage C and Child-Pugh Class A hepatocellular carcinoma patients in prospective clinical trials of systemic therapy
|
Lin Z.-Z.; Chiun Hsu; Hu F.-C.; Shao Y.-Y.; Chang D.-Y.; Yang C.-H.; Hong R.-L.; Hsu C.-H.; Chengb A.-L. |
| 臺大學術典藏 |
2020-04-10T12:51:13Z |
Prognosis of advanced hepatocellular carcinoma patients enrolled in clinical trials can be classified by current staging systems
|
Shao Y.-Y.; Lu L.-C.; Lin Z.-Z.; Chiun Hsu; Shen Y.-C.; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:51:11Z |
A pilot study of hepatic arterial infusion of chemotherapy for patients with advanced hepatocellular carcinoma who have failed anti-angiogenic therapy
|
Shao Y.-Y.; Liang P.-C.; Wu Y.-M.; Huang C.-C.; Huang K.-W.; Cheng J.C.; Hsu C.-H.; Chiun Hsu; Cheng A.-L.; Lin Z.-Z. |
| 臺大學術典藏 |
2020-04-10T12:51:10Z |
Phase ii multicentered study of low-dose everolimus plus cisplatin and weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin as first-line treatment for patients with advanced gastric cancer
|
Su W.-C.; Chao Y.; Yeh K.-H.; Cheng A.-L.; Chen L.-T.; Lin Z.-Z.; Shen Y.-C.; Li C.-P.; Yen C.-J.; Chiun Hsu; Lin Y.-L.; Shen Y.-C.;Li C.-P.;Yen C.-J.;Chiun Hsu;Lin Y.-L.;Lin Z.-Z.;Chen L.-T.;Su W.-C.;Chao Y.;Yeh K.-H.;Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:51:10Z |
Radiofrequency ablation is superior to ethanol injection in early-stage hepatocellular carcinoma irrespective of tumor size
|
Lin Z.-Z.; Shau W.-Y.; Chiun Hsu; Shao Y.-Y.; Yeh Y.-C.; Kuo R.N.-C.; Hsu C.-H.; Yang J.C.-H.; Cheng A.-L.; Lai M.-S. |
| 臺大學術典藏 |
2020-04-10T12:51:09Z |
Potential synergistic anti-tumor activity between lenalidomide and sorafenib in hepatocellular carcinoma
|
Ou D.-L.; Chang C.-J.; Jeng Y.-M.; Lin Y.-J.; Lin Z.-Z.; Gandhi A.K.; Liao S.-C.; Huang Z.-M.; Chiun Hsu; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:51:05Z |
The prognostic impact of type 2 diabetes mellitus on early cervical cancer in Asia
|
Kuo H.-Y.;Lin Z.-Z.;Kuo R.;Shau W.-Y.;Lai C.-L.;Yang Y.-Y.;Shao Y.-Y.;Chiun Hsu;Cheng W.-F.;Cheng A.-L.;Yang J.C.H.;Lai M.-S.; Kuo H.-Y.; Lin Z.-Z.; Kuo R.; Shau W.-Y.; Lai C.-L.; Yang Y.-Y.; Shao Y.-Y.; Chiun Hsu; Cheng W.-F.; Cheng A.-L.; Yang J.C.H.; Lai M.-S. |
| 臺大學術典藏 |
2020-04-10T12:51:01Z |
Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy
|
Shao Y.-Y.;Chen B.-B.;Ou D.-L.;Lin Z.-Z.;Hsu C.-H.;Wang M.-J.;Cheng A.-L.;Chiun Hsu; Shao Y.-Y.; Chen B.-B.; Ou D.-L.; Lin Z.-Z.; Hsu C.-H.; Wang M.-J.; Cheng A.-L.; Chiun Hsu |
| 臺大學術典藏 |
2020-04-10T12:16:14Z |
Hepatic arterial infusion of chemotherapy for advanced hepatocellular carcinoma
|
Lin Z.-Z.; Liang P.; Huang C.; YU-YUN SHAO |
| 臺大學術典藏 |
2020-04-10T12:16:14Z |
Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma
|
Cheng A.-L.; Hsu C.; Ding Y.-H.; YU-YUN SHAO; Chen P.-J.; Lin Z.-Z.; Shen Y.-C.; Hsu C.-H. |
| 臺大學術典藏 |
2020-04-10T12:16:14Z |
Gastric perforation presenting as empyema in a patient with pancreatic cancer on bevacizumab treatment
|
Tien Y.-W.; Cheng A.-L.; Liang P.-C.; YU-YUN SHAO; Lin Z.-Z. |
| 臺大學術典藏 |
2020-04-10T12:16:13Z |
Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma
|
YU-YUN SHAO; Lin Z.-Z.; Hsu C.; Shen Y.-C.; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:16:12Z |
Efficacy, safety, and potential biomarkers of thalidomide plus metronomic chemotherapy for advanced hepatocellular carcinoma
|
YU-YUN SHAO; Lin Z.-Z.; Hsu C.; Lee K.-D.; Hsiao C.-H.; Lu Y.-S.; Huang C.-C.; Shen Y.-C.; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:16:12Z |
High circulating endothelial progenitor levels associated with poor survival of advanced hepatocellular carcinoma patients receiving sorafenib combined with metronomic chemotherapy
|
YU-YUN SHAO; Lin Z.-Z.; Chen T.-J.; Hsu C.; Shen Y.-C.; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:16:12Z |
Impact of baseline hepatitis B viral DNA levels on survival of patients with advanced hepatocellular carcinoma
|
YU-YUN SHAO; Chen P.-J.; Lin Z.-Z.; Huang C.-C.; Ding Y.-H.; Lee Y.-H.; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:16:11Z |
Diabetes mellitus is associated with increased mortality in patients receiving curative therapy for hepatocellular carcinoma
|
Shau W.-Y.; YU-YUN SHAO; Yeh Y.-C.; Lin Z.-Z.; Kuo R.; Hsu C.-H.; Hsu C.; Cheng A.-L.; Lai M.-S. |
| 臺大學術典藏 |
2020-04-10T12:16:11Z |
Survival of patients with small cell lung carcinoma in Taiwan
|
Kuo Y.-H.; Lin Z.-Z.; Yang Y.-Y.; YU-YUN SHAO; Shau W.-Y.; Kuo R.N.C.; Yang J.C.-H.; Lai M.-S. |
| 臺大學術典藏 |
2020-04-10T12:16:10Z |
Prognosis of advanced hepatocellular carcinoma patients enrolled in clinical trials can be classified by current staging systems
|
YU-YUN SHAO; Lu L.-C.; Lin Z.-Z.; Hsu C.; Shen Y.-C.; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:16:10Z |
Survival following surgery with or without adjuvant chemotherapy for stage I-IIIA non-small cell lung cancer: An East Asian population-based study
|
Lin Z.-Z.; Shau W.-Y.; YU-YUN SHAO; Yang Y.-Y.; Kuo R.N.-C.; Yang J.C.-H.; Laie M.-S. |
| 臺大學術典藏 |
2020-04-10T12:16:09Z |
Hospital volume of percutaneous radiofrequency ablation is closely associated with treatment outcomes for patients with hepatocellular carcinoma
|
Kuo R.N.C.; Lin Z.-Z.; Yeh Y.-C.; Shau W.-Y.; Hsu C.-H.; Cheng A.-L.; Lai M.-S.; Lu L.-C.; YU-YUN SHAO |
| 臺大學術典藏 |
2020-04-10T12:16:09Z |
Comparison of gefitinib and erlotinib efficacies as third-line therapy for advanced non-small-cell lung cancer
|
YU-YUN SHAO; Shau W.-Y.; Lin Z.-Z.; Chen H.-M.; Kuo R.; Yang J.C.-H.; Lai M.-S. |
| 臺大學術典藏 |
2020-04-10T12:16:08Z |
Radiofrequency ablation is superior to ethanol injection in early-stage hepatocellular carcinoma irrespective of tumor size
|
Lin Z.-Z.; Shau W.-Y.; Hsu C.; YU-YUN SHAO; Yeh Y.-C.; Kuo R.N.-C.; Hsu C.-H.; Yang J.C.-H.; Cheng A.-L.; Lai M.-S. |
| 臺大學術典藏 |
2020-04-10T12:16:07Z |
Type 2 diabetes mellitus is associated with increased mortality in chinese patients receiving curative surgery for colon cancer
|
Chen K.-H.;Yu-Yun Shao;Lin Z.-Z.;Yeh Y.-C.;Wen-Yi S.;Kuo R.N.;Chen H.-M.;Lai C.-L.;Yeh K.-H.;Cheng A.-L.;Lai M.-S.; Chen K.-H.; YU-YUN SHAO; Lin Z.-Z.; Yeh Y.-C.; Wen-Yi S.; Kuo R.N.; Chen H.-M.; Lai C.-L.; Yeh K.-H.; Cheng A.-L.; Lai M.-S. |
| 臺大學術典藏 |
2020-04-10T12:16:04Z |
Young patients with colorectal cancer have increased risk of second primary cancers
|
Liang Y.-H.;Yu-Yun Shao;Chen H.-M.;Lai C.-L.;Lin Z.-Z.;Kuo R.N.;Cheng A.-L.;Yeh K.-H.;Lai M.-S.; Liang Y.-H.; YU-YUN SHAO; Chen H.-M.; Lai C.-L.; Lin Z.-Z.; Kuo R.N.; Cheng A.-L.; Yeh K.-H.; Lai M.-S. |
| 臺大學術典藏 |
2020-04-10T12:16:04Z |
Comparative effectiveness of first-line platinum-based chemotherapy regimens for advanced lung squamous cell carcinoma
|
Liao B.-C.;Yu-Yun Shao;Chen H.-M.;Shau W.-Y.;Lin Z.-Z.;Kuo R.N.;Lai C.-L.;Chen K.-H.;Cheng A.-L.;Yang J.C.-H.;Lai M.-S.; Liao B.-C.; YU-YUN SHAO; Chen H.-M.; Shau W.-Y.; Lin Z.-Z.; Kuo R.N.; Lai C.-L.; Chen K.-H.; Cheng A.-L.; Yang J.C.-H.; Lai M.-S. |
| 臺大學術典藏 |
2020-04-10T12:16:03Z |
The prognostic impact of type 2 diabetes mellitus on early cervical cancer in Asia
|
Kuo H.-Y.;Lin Z.-Z.;Kuo R.;Shau W.-Y.;Lai C.-L.;Yang Y.-Y.;Yu-Yun Shao;Hsu C.;Cheng W.-F.;Cheng A.-L.;Yang J.C.H.;Lai M.-S.; Kuo H.-Y.; Lin Z.-Z.; Kuo R.; Shau W.-Y.; Lai C.-L.; Yang Y.-Y.; YU-YUN SHAO; Hsu C.; Cheng W.-F.; Cheng A.-L.; Yang J.C.H.; Lai M.-S. |
| 臺大學術典藏 |
2020-04-10T12:16:02Z |
Statin Use Is Associated With Improved Prognosis of Colorectal Cancer in Taiwan
|
Yeh Y.-C.; Lai C.-L.; Lin Z.-Z.; Cheng A.-L.; Lai M.-S.; Yu-Yun Shao;Hsu C.-H.;Yeh K.-H.;Chen H.-M.;Yeh Y.-C.;Lai C.-L.;Lin Z.-Z.;Cheng A.-L.;Lai M.-S.; YU-YUN SHAO; Hsu C.-H.; Yeh K.-H.; Chen H.-M. |
| 臺大學術典藏 |
2020-04-10T12:16:00Z |
Lenalidomide as second-line therapy for advanced hepatocellular carcinoma (HCC): biomarker exploration
|
YU-YUN SHAO; Chen B.-B.; Lin Z.-Z.; Hsu C.-H.; Wang M.-J.; Cheng A.-L.; Hsu C. |
| 臺大學術典藏 |
2020-04-10T12:15:59Z |
Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC)
|
Chen Y.-C.; Ohishi N.; O’Neil B.; Schwartz L.; Smith-Jones P.M.; Ohtomo T.; Tanaka T.; Morikawa H.; Maki Y.; Frenette C.; Lin Z.-Z.; YU-YUN SHAO; Wan P.; Ma J.; Lyashchenko S.K.; Gansukh B.; Pandit-Taskar N.; Ruan S.; Beylergil V.; O’Donoghue J.; Abou-Alfa G.K.;Yen C.-J.;Hsu C.-H.;O’Donoghue J.;Beylergil V.;Ruan S.;Pandit-Taskar N.;Gansukh B.;Lyashchenko S.K.;Ma J.;Wan P.;Yu-Yun Shao;Lin Z.-Z.;Frenette C.;O’Neil B.;Schwartz L.;Smith-Jones P.M.;Ohtomo T.;Tanaka T.;Morikawa H.;Maki Y.;Ohishi N.;Chen Y.-C.;Agajanov T.;Boisserie F.;Di Laurenzio L.;Lee R.;Larson S.M.;Cheng A.-L.;Carrasquilo J.A.; Abou-Alfa G.K.; Yen C.-J.; Hsu C.-H.; Agajanov T.; Boisserie F.; Di Laurenzio L.; Lee R.; Larson S.M.; Cheng A.-L.; Carrasquilo J.A. |
| 臺大學術典藏 |
2020-04-10T12:15:58Z |
Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy
|
Yu-Yun Shao;Chen B.-B.;Ou D.-L.;Lin Z.-Z.;Hsu C.-H.;Wang M.-J.;Cheng A.-L.;Hsu C.; YU-YUN SHAO; Chen B.-B.; Ou D.-L.; Lin Z.-Z.; Hsu C.-H.; Wang M.-J.; Cheng A.-L.; Hsu C. |
| 臺大學術典藏 |
2020-04-10T12:15:55Z |
Considerations of heterogeneity in clinical trials for hepatocellular carcinoma
|
Liu T.-H.;Yu-Yun Shao;Lu L.-C.;Shen Y.-C.;Hsu C.;Lin Z.-Z.;Hsu C.-H.;Cheng A.-L.; Liu T.-H.; YU-YUN SHAO; Lu L.-C.; Shen Y.-C.; Hsu C.; Lin Z.-Z.; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:15:53Z |
Early alpha-foetoprotein response associated with treatment efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma
|
Yu-Yun Shao;Liu T.-H.;Hsu C.;Lu L.-C.;Shen Y.-C.;Lin Z.-Z.;Cheng A.-L.;Hsu C.-H.; YU-YUN SHAO; Liu T.-H.; Hsu C.; Lu L.-C.; Shen Y.-C.; Lin Z.-Z.; Cheng A.-L.; Hsu C.-H. |
| 臺大學術典藏 |
2020-04-09T09:39:09Z |
Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy
|
Shao, Y. Y.; Chen, B. B.; Ou, D. L.; Lin, Z. Z.; Hsu, C. H.; Wang, M. J.; Cheng, A. L.; Hsu, C. |
| 臺大學術典藏 |
2020-03-30T08:50:53Z |
Real-world data on prognostic factors for overall survival in EGFR mutation-positive advanced non-small cell lung cancer patients treated with first-line gefitinib
|
Shih J.-Y.; JIN-SHING CHEN; Lin Z.-Z.; Lin C.-C.; Yang J.C.H.; Yu C.-J.; Yao Z.-H.;Liao W.-Y.;Ho C.-C.;Chen K.-Y.;Shih J.-Y.;Jin-Shing Chen;Lin Z.-Z.;Lin C.-C.;Yang J.C.H.;Yu C.-J.; Yao Z.-H.; Liao W.-Y.; Ho C.-C.; Chen K.-Y. |
| 臺大學術典藏 |
2020-03-30T08:50:44Z |
Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations
|
Yu C.-J.; Yang J.C.-H.; Shih J.-Y.; Lin Z.-Z.; Lee J.-H.; Chen K.-Y.; Yang C.-Y.; Hsu C.-L.; Ho C.-C.; Lin Y.-T.;Jin-Shing Chen;Liao W.-Y.;Ho C.-C.;Hsu C.-L.;Yang C.-Y.;Chen K.-Y.;Lee J.-H.;Lin Z.-Z.;Shih J.-Y.;Yang J.C.-H.;Yu C.-J.; Lin Y.-T.; JIN-SHING CHEN; Liao W.-Y. |
| 臺大學術典藏 |
2020-03-30T08:50:43Z |
Incidence of hepatitis B reactivation during epidermal growth factor receptor tyrosine kinase inhibitor treatment in non–small-cell lung cancer patients
|
Yang J.C.-H.; Yu C.-J.; Lin C.-C.; Shih J.-Y.; JIN-SHING CHEN; Lin Z.-Z.; Chen K.-Y.; Liao W.-Y.; Ho C.-C.; Yao Z.-H.; Yao Z.-H.;Liao W.-Y.;Ho C.-C.;Chen K.-Y.;Shih J.-Y.;Jin-Shing Chen;Lin Z.-Z.;Lin C.-C.;Yang J.C.-H.;Yu C.-J. |
| 臺大學術典藏 |
2020-03-24T09:07:53Z |
Sunitinib-induced myxedema coma
|
Shey-Ying Chen;Kao P.-C.;Lin Z.-Z.;Chiang W.-C.;Fang C.-C.; SHEY-YING CHEN; Kao P.-C.; Lin Z.-Z.; Chiang W.-C.; Fang C.-C. |
| 臺大學術典藏 |
2020-03-24T07:38:04Z |
Sunitinib-induced myxedema coma
|
CHENG-CHUNG FANG; Chiang W.-C.; Lin Z.-Z.; Kao P.-C.; Chen S.-Y.; Chen S.-Y.;Kao P.-C.;Lin Z.-Z.;Chiang W.-C.;Cheng-Chung Fang |
| 臺大學術典藏 |
2020-03-06T08:25:25Z |
Nuclear overexpression of mitotic regulatory proteins in biliary tract cancer: Correlation with clinicopathologic features and patient survival
|
Shen Y.-C.; Hu F.-C.; YUNG-MING JENG; Chang Y.-T.; Lin Z.-Z.; Chang M.-C.; Hsu C.; Cheng A.-L. |
| 臺大學術典藏 |
2020-03-06T08:25:24Z |
The Aurora kinase inhibitor VE-465 has anticancer effects in pre-clinical studies of human hepatocellular carcinoma
|
Cheng A.-L.; Chung Y.; YUNG-MING JENG; Hu F.-C.; Hsu C.; Kuo S.-H.; Chen T.-J.; Huang Y.-F.; Huang C.-Y.F.; Yeh P.-Y.; Hsu C.-H.; Hsu H.-C.; Lin Z.-Z. |
| 臺大學術典藏 |
2020-03-06T08:25:06Z |
Potential synergistic anti-tumor activity between lenalidomide and sorafenib in hepatocellular carcinoma
|
Ou D.-L.;Chang C.-J.;Yung-Ming Jeng;Lin Y.-J.;Lin Z.-Z.;Gandhi A.K.;Liao S.-C.;Huang Z.-M.;Hsu C.;Cheng A.-L.; Ou D.-L.; Chang C.-J.; YUNG-MING JENG; Lin Y.-J.; Lin Z.-Z.; Gandhi A.K.; Liao S.-C.; Huang Z.-M.; Hsu C.; Cheng A.-L. |
| 臺大學術典藏 |
2020-03-06T08:24:47Z |
Klotho-beta and fibroblast growth factor 19 expression correlates with early recurrence of resectable hepatocellular carcinoma
|
Lin Z.-Z.;Hsu C.;Yung-Ming Jeng;Hu F.-C.;Pan H.-W.;Wu Y.-M.;Hsu H.-C.;Cheng A.-L.; Lin Z.-Z.; Hsu C.; YUNG-MING JENG; Hu F.-C.; Pan H.-W.; Wu Y.-M.; Hsu H.-C.; Cheng A.-L. |
| 臺大學術典藏 |
2020-02-20T06:53:16Z |
Gastric perforation presenting as empyema in a patient with pancreatic cancer on bevacizumab treatment
|
Cheng A.-L.; Shao Y.-Y.; Lin Z.-Z.; Liang P.-C.; YU-WEN TIEN |
| 臺大學術典藏 |
2020-02-11T07:58:41Z |
A pilot study of hepatic arterial infusion of chemotherapy for patients with advanced hepatocellular carcinoma who have failed anti-angiogenic therapy
|
Shao Y.-Y.;Liang P.-C.;Yao-Ming Wu;Huang C.-C.;Huang K.-W.;Cheng J.C.;Hsu C.-H.;Hsu C.;Cheng A.-L.;Lin Z.-Z.; Shao Y.-Y.; Liang P.-C.; YAO-MING WU; Huang C.-C.; Huang K.-W.; Cheng J.C.; Hsu C.-H.; Hsu C.; Cheng A.-L.; Lin Z.-Z. |
| 臺大學術典藏 |
2020-02-11T07:58:28Z |
Klotho-beta and fibroblast growth factor 19 expression correlates with early recurrence of resectable hepatocellular carcinoma
|
Lin Z.-Z.;Hsu C.;Jeng Y.-M.;Hu F.-C.;Pan H.-W.;Yao-Ming Wu;Hsu H.-C.;Cheng A.-L.; Lin Z.-Z.; Hsu C.; Jeng Y.-M.; Hu F.-C.; Pan H.-W.; YAO-MING WU; Hsu H.-C.; Cheng A.-L. |
| 臺大學術典藏 |
2020-02-07T01:18:22Z |
Sunitinib-induced myxedema coma
|
Fang C.-C.;WEN-CHU CHIANG;Lin Z.-Z.;Kao P.-C.;Chen S.-Y.; Chen S.-Y.; Kao P.-C.; Lin Z.-Z.; WEN-CHU CHIANG; Fang C.-C. |
| 臺大學術典藏 |
2020-02-06T05:21:56Z |
The prognostic impact of type 2 diabetes mellitus on early cervical cancer in Asia
|
Lai M.-S.;Yang J.C.H.;Cheng A.-L.;WEN-FANG CHENG;Hsu C.;Shao Y.-Y.;Yang Y.-Y.;Lai C.-L.;Shau W.-Y.;Kuo R.;Lin Z.-Z.;Kuo H.-Y.; Kuo H.-Y.; Lin Z.-Z.; Kuo R.; Shau W.-Y.; Lai C.-L.; Yang Y.-Y.; Shao Y.-Y.; Hsu C.; WEN-FANG CHENG; Cheng A.-L.; Yang J.C.H.; Lai M.-S.; Kuo H.-Y.; Lin Z.-Z.; Kuo R.; Shau W.-Y.; Lai C.-L.; Yang Y.-Y.; Shao Y.-Y.; Hsu C.; WEN-FANG CHENG; Cheng A.-L.; Yang J.C.H.; Lai M.-S. |
| 臺大學術典藏 |
2020-01-13T08:25:29Z |
A study of the tool change timing in turning micro V-grooves roller
|
Liao, Y.-S.; Lin, Z.-Z.; Hung, Y.-A.; YUNN-SHIUAN LIAO |
| 臺大學術典藏 |
2020 |
Clinical outcomes and toxicity predictors of thoracic re-irradiation for locoregionally recurrent lung cancer
|
Kuo S.-H.; Cheng A.-L; Yang J.C.-H; Lu S.-H; Lin Z.-Z; Yu C.-J; Yang W.-C; Feng-Ming Hsu; Chen Y.-H; Shih J.-Y |
| 臺大學術典藏 |
2020 |
Clinical outcomes and toxicity predictors of thoracic re-irradiation for locoregionally recurrent lung cancer
|
Yang W.-C.;Hsu F.-M.;Chen Y.-H.;Shih J.-Y.;Chong-Jen Yu;Lin Z.-Z.;Lu S.-H.;Yang J.C.-H.;Cheng A.-L.;Kuo S.-H.; Yang W.-C.; Hsu F.-M.; Chen Y.-H.; Shih J.-Y.; CHONG-JEN YU; Lin Z.-Z.; Lu S.-H.; Yang J.C.-H.; Cheng A.-L.; Kuo S.-H. |
